NTI Neurotech Phase II/III Autism Trial Successfully Meets Primary Endpoint Highlights:
• NTIASD2 Phase II/III clinical trial met the primary endpoint of a statistically significant improvement in severity of illness (CGI-S) at 8 weeks between NTI164 and placebo (p<0.001)
• Children in NTI164 group re-classified from markedly-severely ill (CGI-S: 5.54) at baseline to mild-moderately ill (CGI-S: 3.77) at 8 weeks, a very strong improvement
Seems like great results,
As well as an important product,
That can improve the lives of many people.
As well as having a considerable market size....
One would think some Big Pharma Co's would be sizing this up !!!!
- Forums
- ASX - Day Trading
- Afternoon trading April 17
NTI Neurotech Phase II/III Autism Trial Successfully Meets...
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)